Although chemotherapy can improve the overall survival and prognosis of cancer patients,
chemoresistance remains an obstacle due to the diversity, heterogeneity, and adaptability to …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer. The poor prognosis
calls for a more detailed understanding of disease biology in order to pave the way for the …

Solid tumors are generally characterized by an acidic tumor microenvironment (TME) that
favors cancer progression, therapy resistance and immune evasion. By single-cell RNA …

Lactic acid is one of the most abundant products of cellular metabolism and has historically
been considered a cell-damaging metabolic product. However, as research has deepened …

Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low
operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based …

Pancreatic cancer is characterized by hidden onset, high malignancy, and early metastasis.
Although a few cases meet the surgical indications, chemotherapy remains the primary …

The development of immune checkpoint blockade (ICB) therapies has been instrumental in
advancing the field of immunotherapy. Despite the prominence of these treatments, many …

Simple Summary For a long-time lactic acid has been considered as a toxic end-product of
metabolism that cause different adverse effects. However, in recent decades a plenty of …

Simple Summary Tumor cells display important plasticity potential. Notably, tumor cells have
the ability to change toward immature cells called cancer stem cells under the influence of …

Transmembrane transport of l-lactate by members of the monocarboxylate transporter family,
MCT, is vital in human physiology and a malignancy factor in cancer. Interaction with an …